Zhaoke Ophthalmology-B (06622) Surges Over 7% Intraday as Company Expands AFT Partnership to Singapore and Reaches Vietnam Agreement with Senju

Stock News

Jan 29

Zhaoke Ophthalmology-B (06622) saw its shares surge more than 7% during the trading session. As of the time of writing, the stock was up 3.44%, trading at HK$3.61, with a turnover of HK$11.43 million.

On January 26, Zhaoke Ophthalmology announced it has granted exclusive commercialization rights for its core presbyopia treatment drug, BRIMOCHOL™ PF, in Singapore and Vietnam to New Zealand's AFT Pharmaceuticals and Japan's Senju Pharmaceutical, respectively.

This move extends Zhaoke Ophthalmology's global commercial footprint to eight markets: South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan, Singapore, and Vietnam.

Under the agreements, Zhaoke Ophthalmology has granted AFT exclusive distribution rights in Singapore and Senju exclusive distribution rights in Vietnam.

AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company whose core business model focuses on developing and licensing products in over 125 countries worldwide.

Senju Pharmaceutical is a research-driven private Japanese pharmaceutical company with years of specialization in the ophthalmology field, aiming to enhance global patients' vision health through original medications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179934118"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179934118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179934118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-29 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179934118","market":"us","top_or_hot":-1,"title":"Zhaoke Ophthalmology-B (06622) Surges Over 7% Intraday as Company Expands AFT Partnership to Singapore and Reaches Vietnam Agreement with Senju","media":"Stock News","content":"<p>Zhaoke Ophthalmology-B (06622) saw its shares surge more than 7% during the trading session. As of the time of writing, the stock was up 3.44%, trading at HK$3.61, with a turnover of HK$11.43 million.</p>\n<p>On January 26, Zhaoke Ophthalmology announced it has granted exclusive commercialization rights for its core presbyopia treatment drug, BRIMOCHOL™ PF, in Singapore and Vietnam to New Zealand's AFT Pharmaceuticals and Japan's Senju Pharmaceutical, respectively.</p>\n<p>This move extends Zhaoke Ophthalmology's global commercial footprint to eight markets: South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan, Singapore, and Vietnam.</p>\n<p>Under the agreements, Zhaoke Ophthalmology has granted AFT exclusive distribution rights in Singapore and Senju exclusive distribution rights in Vietnam.</p>\n<p>AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company whose core business model focuses on developing and licensing products in over 125 countries worldwide.</p>\n<p>Senju Pharmaceutical is a research-driven private Japanese pharmaceutical company with years of specialization in the ophthalmology field, aiming to enhance global patients' vision health through original medications.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology-B (06622) Surges Over 7% Intraday as Company Expands AFT Partnership to Singapore and Reaches Vietnam Agreement with Senju</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology-B (06622) Surges Over 7% Intraday as Company Expands AFT Partnership to Singapore and Reaches Vietnam Agreement with Senju\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-29 16:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhaoke Ophthalmology-B (06622) saw its shares surge more than 7% during the trading session. As of the time of writing, the stock was up 3.44%, trading at HK$3.61, with a turnover of HK$11.43 million.</p>\n<p>On January 26, Zhaoke Ophthalmology announced it has granted exclusive commercialization rights for its core presbyopia treatment drug, BRIMOCHOL™ PF, in Singapore and Vietnam to New Zealand's AFT Pharmaceuticals and Japan's Senju Pharmaceutical, respectively.</p>\n<p>This move extends Zhaoke Ophthalmology's global commercial footprint to eight markets: South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan, Singapore, and Vietnam.</p>\n<p>Under the agreements, Zhaoke Ophthalmology has granted AFT exclusive distribution rights in Singapore and Senju exclusive distribution rights in Vietnam.</p>\n<p>AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company whose core business model focuses on developing and licensing products in over 125 countries worldwide.</p>\n<p>Senju Pharmaceutical is a research-driven private Japanese pharmaceutical company with years of specialization in the ophthalmology field, aiming to enhance global patients' vision health through original medications.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1179934118","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179934118","pubTimestamp":1769673622,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhaoke Ophthalmology-B (06622) saw its shares surge more than 7% during the trading session. As of the time of writing, the stock was up 3.44%, trading at HK$3.61, with a turnover of HK$11.43...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","AFT":"Apollo Senior Floating Rate Fund","BK1583":"高瓴概念","BK1191":"制药","06622":"兆科眼科-B","BK4588":"碎股","BK1587":"次新股","BK1574":"生物医药B类股","VT":"世界全股市ETF-Vanguard"},"translate_title":"兆科眼科-B(06622)盘中大涨超7%，因公司将AFT合作伙伴关系扩展至新加坡并与Senju达成越南协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VT":1,"06622":1,"AFT":1},"content_text":"Zhaoke Ophthalmology-B (06622) saw its shares surge more than 7% during the trading session. As of the time of writing, the stock was up 3.44%, trading at HK$3.61, with a turnover of HK$11.43 million.\nOn January 26, Zhaoke Ophthalmology announced it has granted exclusive commercialization rights for its core presbyopia treatment drug, BRIMOCHOL™ PF, in Singapore and Vietnam to New Zealand's AFT Pharmaceuticals and Japan's Senju Pharmaceutical, respectively.\nThis move extends Zhaoke Ophthalmology's global commercial footprint to eight markets: South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan, Singapore, and Vietnam.\nUnder the agreements, Zhaoke Ophthalmology has granted AFT exclusive distribution rights in Singapore and Senju exclusive distribution rights in Vietnam.\nAFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company whose core business model focuses on developing and licensing products in over 125 countries worldwide.\nSenju Pharmaceutical is a research-driven private Japanese pharmaceutical company with years of specialization in the ophthalmology field, aiming to enhance global patients' vision health through original medications.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}